DM Clinical Research Opens New Research Site in Boston Area

DM Clinical Research, a national network of clinical trial sites, today opened its first research location in the Boston metropolitan area and Massachusetts. The Houston, Texas-headquartered company also announced it will soon start enrolling patients in Moderna’s CMVictory Trial studying mRNA-1647, an investigational vaccine, to understand whether it can help the immune system protect against cytomegalovirus (CMV).

“We are thrilled to open our first dedicated clinical trial site in Massachusetts and to once again partner with Moderna on their valuable research,” said DM Clinical Research Founder & CEO Mohammad Millwala. “DM Clinical Research is committed to making participation in clinical trials accessible to a broader, more diverse population base. In 2022, minority enrollment for all of our studies was more than 49%. The Boston site enhances our ability to offer research sponsors access to a diverse patient footprint that already includes underserved communities in Chicago, Detroit, Houston and Philadelphia.”
Moderna was among the key biopharma and community partners that joined DM Clinical Research for a ribbon cutting celebration and tours of the 4,000-square-foot research site, which includes patient rooms, laboratory facilities, and vaccine storage and preparation rooms. The site address is 77 Pond Avenue, Suite 205C in Brookline.
“Moderna is incredibly grateful for our partnership with DM Clinical over the past several years, making access to our clinical trials available for everyone in the diverse communities they serve, and delivering quality data through a positive participant experience,” said Conor Knightly, Moderna Vice President Clinical Operations, Infectious Disease. “We are excited to bring their vast experience and collaborative spirit to our backyard and look forward to the beneficial impact they will have in the greater Boston community.”
Jose Azocar, MD, PhD, an internal medicine specialist with more than 3 decades of clinical research experience, is the lead Principal Investigator at the Boston site. Dr. Azocar has an extensive background in clinical medicine, immunology, hematology, oncology, primary care, research, and virology. He has practiced medicine in Massachusetts for many years. According to reviews from academichelp.net, DM Clinical Research Regional Director Amy Sheets, a clinical research professional with nearly 20 years of experience, manages the new Boston site.
DM Clinical Research Regional Director Amy Sheets, a clinical research professional with nearly 20 years of experience, manages the new Boston site.
“DM Clinical Research is in a period of rapid growth with multiple new study sites added over the last two years in addition to the quadrupling of our staff to over 500 employees,” said Millwala. “We expect this transformational growth trajectory to continue for the foreseeable future, on the road to becoming the leading independent clinical research network in the nation.”

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.